Literature DB >> 21852384

A mutation threshold distinguishes the antitumorigenic effects of the mitochondrial gene MTND1, an oncojanus function.

Giuseppe Gasparre1, Ivana Kurelac, Mariantonietta Capristo, Luisa Iommarini, Anna Ghelli, Claudio Ceccarelli, Giordano Nicoletti, Patrizia Nanni, Carla De Giovanni, Katia Scotlandi, Christine M Betts, Valerio Carelli, Pier Luigi Lollini, Giovanni Romeo, Michela Rugolo, Anna Maria Porcelli.   

Abstract

The oncogenic versus suppressor roles of mitochondrial genes have long been debated. Peculiar features of mitochondrial genetics such as hetero/homoplasmy and mutation threshold are seldom taken into account in this debate. Mitochondrial DNA (mtDNA) mutations generally have been claimed to be protumorigenic, but they are also hallmarks of mostly benign oncocytic tumors wherein they help reduce adaptation to hypoxia by destabilizing hypoxia-inducible factor-1α (HIF1α). To determine the influence of a disassembling mtDNA mutation and its hetero/homoplasmy on tumorigenic and metastatic potential, we injected mice with tumor cells harboring different loads of the gene MTND1 m.3571insC. Cell cultures obtained from tumor xenografts were then analyzed to correlate energetic competence, apoptosis, α-ketoglutarate (α-KG)/succinate (SA) ratio, and HIF1α stabilization with the mutation load. A threshold level for the antitumorigenic effect of MTND1 m.3571insC mutation was defined, above which tumor growth and invasiveness were reduced significantly. Notably, HIF1α destabilization and downregulation of HIF1α-dependent genes occurred in cells and tumors lacking complex I (CI), where there was an associated imbalance of α-KG/SA despite the presence of an actual hypoxic environment. These results strongly implicate mtDNA mutations as a cause of oncocytic transformation. Thus, the antitumorigenic and antimetastatic effects of high loads of MTND1 m.3571insC, following CI disassembly, define a novel threshold-regulated class of cancer genes. We suggest these genes be termed oncojanus genes to recognize their ability to contribute either oncogenic or suppressive functions in mitochondrial settings during tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21852384     DOI: 10.1158/0008-5472.CAN-11-1042

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  27 in total

1.  Metformin sensitizes endometrial cancer cells to chemotherapy through IDH1-induced Nrf2 expression via an epigenetic mechanism.

Authors:  Mingzhu Bai; Linlin Yang; Hong Liao; Xiaoyan Liang; Bingying Xie; Ji Xiong; Xiang Tao; Xiong Chen; Yali Cheng; Xiaojun Chen; Youji Feng; Zhenbo Zhang; Wenxin Zheng
Journal:  Oncogene       Date:  2018-06-19       Impact factor: 9.867

2.  Stable nuclear expression of ATP8 and ATP6 genes rescues a mtDNA Complex V null mutant.

Authors:  Amutha Boominathan; Shon Vanhoozer; Nathan Basisty; Kathleen Powers; Alexandra L Crampton; Xiaobin Wang; Natalie Friedricks; Birgit Schilling; Martin D Brand; Matthew S O'Connor
Journal:  Nucleic Acids Res       Date:  2016-09-04       Impact factor: 16.971

3.  Targeting the mitochondrial trifunctional protein restrains tumor growth in oxidative lung carcinomas.

Authors:  Nivea Dias Amoedo; Saharnaz Sarlak; Emilie Obre; Pauline Esteves; Hugues Bégueret; Yann Kieffer; Benoît Rousseau; Alexis Dupis; Julien Izotte; Nadège Bellance; Laetitia Dard; Isabelle Redonnet-Vernhet; Giuseppe Punzi; Mariana Figueiredo Rodrigues; Elodie Dumon; Walid Mafhouf; Véronique Guyonnet-Dupérat; Lara Gales; Tony Palama; Floriant Bellvert; Nathalie Dugot-Senan; Stéphane Claverol; Jean-Marc Baste; Didier Lacombe; Hamid Reza Rezvani; Ciro Leonardo Pierri; Fatima Mechta-Grigoriou; Matthieu Thumerel; Rodrigue Rossignol
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

Review 4.  Relevance of mitochondrial genetics and metabolism in cancer development.

Authors:  Giuseppe Gasparre; Anna Maria Porcelli; Giorgio Lenaz; Giovanni Romeo
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-02-01       Impact factor: 10.005

5.  Release of targeted p53 from the mitochondrion as an early signal during mitochondrial dysfunction.

Authors:  M L Green; M M Pisano; R A Prough; T B Knudsen
Journal:  Cell Signal       Date:  2013-07-27       Impact factor: 4.315

6.  A platform independent RNA-Seq protocol for the detection of transcriptome complexity.

Authors:  Claudia Calabrese; Marina Mangiulli; Caterina Manzari; Anna Maria Paluscio; Mariano Francesco Caratozzolo; Flaviana Marzano; Ivana Kurelac; Anna Maria D'Erchia; Domenica D'Elia; Flavio Licciulli; Sabino Liuni; Ernesto Picardi; Marcella Attimonelli; Giuseppe Gasparre; Anna Maria Porcelli; Graziano Pesole; Elisabetta Sbisà; Apollonia Tullo
Journal:  BMC Genomics       Date:  2013-12-05       Impact factor: 3.969

7.  Identification and functional prediction of mitochondrial complex III and IV mutations associated with glioblastoma.

Authors:  Rhiannon E Lloyd; Kathleen Keatley; D Timothy J Littlewood; Brigitte Meunier; William V Holt; Qian An; Samantha C Higgins; Stavros Polyzoidis; Katie F Stephenson; Keyoumars Ashkan; Helen L Fillmore; Geoffrey J Pilkington; John E McGeehan
Journal:  Neuro Oncol       Date:  2015-03-02       Impact factor: 12.300

8.  Enhanced tumorigenicity by mitochondrial DNA mild mutations.

Authors:  Alberto Cruz-Bermúdez; Carmen G Vallejo; Ramiro J Vicente-Blanco; María Esther Gallardo; Miguel Ángel Fernández-Moreno; Miguel Quintanilla; Rafael Garesse
Journal:  Oncotarget       Date:  2015-05-30

9.  A multi-parametric workflow for the prioritization of mitochondrial DNA variants of clinical interest.

Authors:  Mariangela Santorsola; Claudia Calabrese; Giulia Girolimetti; Maria Angela Diroma; Giuseppe Gasparre; Marcella Attimonelli
Journal:  Hum Genet       Date:  2015-11-30       Impact factor: 4.132

10.  Respiratory complex I is essential to induce a Warburg profile in mitochondria-defective tumor cells.

Authors:  Claudia Calabrese; Luisa Iommarini; Ivana Kurelac; Maria Antonietta Calvaruso; Mariantonietta Capristo; Pier-Luigi Lollini; Patrizia Nanni; Christian Bergamini; Giordano Nicoletti; Carla De Giovanni; Anna Ghelli; Valentina Giorgio; Mariano Francesco Caratozzolo; Flaviana Marzano; Caterina Manzari; Christine M Betts; Valerio Carelli; Claudio Ceccarelli; Marcella Attimonelli; Giovanni Romeo; Romana Fato; Michela Rugolo; Apollonia Tullo; Giuseppe Gasparre; Anna Maria Porcelli
Journal:  Cancer Metab       Date:  2013-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.